FdaApplication
NDA 220073
Identifiers
- fda_app_no: NDA220073
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2025-04-17 |
Revenue by product
ELIQUIS
| Period | Revenue |
|---|---|
| Q2 2026 | $4.5B |
| Q1 2026 | $4.1B |
| Q4 2025 | $3.5B |
| Q3 2025 | $3.7B |
| Q2 2025 | $3.7B |
| Q1 2025 | $3.6B |
| Q4 2024 | $3.2B |
| Q3 2024 | $3.0B |
| Q2 2024 | $3.4B |
| Q1 2024 | $3.7B |
| Q4 2023 | $2.9B |
| Q3 2023 | $2.7B |
| Q2 2023 | $3.2B |
| Q1 2023 | $3.4B |
| Q4 2022 | $2.7B |
| Q3 2022 | $2.7B |
| Q2 2022 | $3.2B |
| Q1 2022 | $3.2B |
| Q4 2021 | $2.7B |
| Q3 2021 | $2.4B |
| Q2 2021 | $2.8B |
| Q1 2021 | $2.9B |
| Q4 2020 | $2.3B |
| Q3 2020 | $2.1B |
| Q2 2020 | $2.2B |
| Q1 2020 | $2.6B |
| Q4 2019 | $2.0B |
| Q3 2019 | $1.9B |
| Q2 2019 | $2.0B |
| Q1 2019 | $1.9B |
| Q4 2018 | $1.7B |
| Q3 2018 | $1.6B |
| Q2 2018 | $1.6B |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ELIQUIS | APIXABAN | 0.5MG | TABLET;ORAL |
| ELIQUIS | APIXABAN | 0.15MG | SUSPENSION;ORAL |
| ELIQUIS | APIXABAN | 5MG | TABLET;ORAL |
| ELIQUIS SPRINKLE | APIXABAN | 0.15MG | FOR SUSPENSION;ORAL |
4 products